MedTrace Logo

Haplo HCT vs Haplo-cord HCT for Patients With AML

NCT03719534 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2023-06-27

No results posted yet for this study

Summary

Patients who have acute myeloid leukemia and will undergo haplo-identical donor hematopoeitic cell transplantation (haplo HCT) are potential candidates of this trial. Participants will randomized into two arms: Arm A will undergo a typical haplo HCT, while Arm B will receive an coinfusion of an unrelated cord blood unit (haplo-cord HCT) in addition to Arm A. Progression-free survival, overall survival, cumulative incidence of relapse and nonrelapse mortality will be recorded as endpoints.

Conditions

Interventions

PROCEDURE

haplo-HCT

HCT will be performed with a haploidentical donor

PROCEDURE

haplo-cord HCT

Haploidentical donor HCT will be performed with coinfusion of unrelated cord blood unit

Sponsors & Collaborators

  • Zhejiang University

    collaborator OTHER

  • The Second People's Hospital of Huai'an

    collaborator OTHER

  • Soochow Hopes Hematology Hospital

    collaborator UNKNOWN

  • Hygeia Suzhou Yongding Hospital

    collaborator UNKNOWN

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Depei Wu, M.D., Ph.D. · The First Affiliated Hospital of Soochow University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2022-12-31
Completion
2023-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03719534 on ClinicalTrials.gov